[Home](https://github.com/mm80843/T3.5/blob/main/docs/index.md) >> Class: [Risk](https://github.com/mm80843/T3.5/tree/main/docs/Risk/index.md) >> Individual ID:PBN__Risk_1783 

# __Delayed drug development__

## Category to which it belongs

* [Supply chain and labor issues affecting project timelines, costs, and delivery are causing significant disruptions and setbacks.](https://github.com/mm80843/T3.5/blob/main/docs/PBNCategory/PBN__PBNCategory_140.md)

## Closest similar item

* [Slow drug development](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_466.md)
* [Development of drugs](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_431.md)
* [Delayed treatment](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_3219.md)
* [Lack of effective drugs](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_2684.md)
* [Lack of effective pharmaceutical response](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1589.md)
* [Lack of drug therapy options](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1139.md)
* [Slowed development, lack of progress](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_3202.md)
* [Lack of accessibility of pharmaceutical interventions in developing countries](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_727.md)
* [Lack of access to pharmaceutical interventions](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1151.md)
* [Insufficient non-pharmaceutical interventions](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1590.md)

## Description of the risk

Slow process of drug testing and discovery

## Is the risk affecting GBN scales

* [No](https://github.com/mm80843/T3.5/blob/main/docs/RiskGBN/PBN__RiskGBN_0.md)

## Type of the risk

* [Physical](https://github.com/mm80843/T3.5/blob/main/docs/RiskHealth/PBN__RiskHealth_0.md)

## Type of impact of the risk (according to ISO37100)

* [Biodiversity and ecosystem services](https://github.com/mm80843/T3.5/blob/main/docs/RiskISO/PBN__RiskISO_Purpose_4.md)

## Type of purpose of the risk (according to ISO37100)

* [Economy and sustainable production and consumption](https://github.com/mm80843/T3.5/blob/main/docs/RiskISO/PBN__RiskISO_Impact_10.md)

## Mitigations of this risk

* [Utilize ai methods for faster drug testing and discovery](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2376.md)

## Name of the risk

Limited treatment options and prolonged pandemic

## Stakeholders who can mitigate this risk

* [Researchers](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_2.md)
* [Drug developers](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_1196.md)

## Articles mentionning the risk

* [Exploring the Potential of Artificial Intelligence and Machine Learning to Combat COVID-19 and Existing Opportunities for LMIC: A Scoping Review](https://github.com/mm80843/T3.5/blob/main/docs/Article/PBN__Article_131.md)

## People affected by this risk

* [Researchers](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_2.md)
* [Pharmaceutical companies](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_124.md)

## Technologies linked to the risk

* [None](https://github.com/mm80843/T3.5/blob/main/docs/Technology/PBN__Technology_35.md)

## Property: has_RiskType

* [Technological](https://github.com/mm80843/T3.5/blob/main/docs/RiskType/PBN__RiskType_5.md)

